4C Biomed

Company Overview

Snapshot

Founded in February 2016 by Eyal Greenberg and Gal Markel, 4C Biomed operates with 1–10 employees. The company has secured funding across one round, with Israel Biotech Fund participating as an investor. 4C Biomed is developing an IND-ready asset, with plans to enter clinical Phase I in 2026.

Business overview

4C Biomed is a Health Tech & Life Sciences company focused on the research and development of immuno-oncology therapies. The company leverages cutting-edge science, clinical insights, and unique autologous cell systems to identify novel immuno-oncology targets. Its core technology includes a sensitive, immunological-based screening platform designed to accelerate the journey from discovery to clinical application. 4C Biomed operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Pharmaceuticals market.

Company Intelligence Q&A

When was 4C Biomed founded and by whom?

4C Biomed was founded in February 2016 by co-founders Eyal Greenberg and Gal Markel.

What is 4C Biomed's primary focus in drug development?

4C Biomed focuses on the research and development of immuno-oncology therapies, utilizing autologous cell systems to identify novel immune checkpoint inhibitor targets.

What is the status of 4C Biomed's lead drug candidate?

4C Biomed's lead drug is an IND-ready asset, with plans to enter clinical Phase I in 2026.

What is 4C Biomed's core technological approach?

4C Biomed employs a uniquely sensitive, immunological-based screening platform to identify novel immuno-oncology targets and accelerate their translation to clinical application.